Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies.

1987 ◽  
Vol 5 (12) ◽  
pp. 1890-1899 ◽  
Author(s):  
A A Epenetos ◽  
A J Munro ◽  
S Stewart ◽  
R Rampling ◽  
H E Lambert ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Monoclonal Antibodies ◽  
Small Volume ◽  
Intraperitoneal Administration ◽  
Advanced Ovarian Cancer ◽  
Tumor Diameter ◽  
External Beam Irradiation ◽  
Effective Form ◽  
Acute Side Effects ◽  
Treatment Analysis

Twenty-four patients with persistent epithelial ovarian cancer after chemotherapy with or without external beam irradiation, were treated with intraperitoneally administered 131I-labeled monoclonal antibodies HMFG1, HMFG2, AUA1, H17E2, directed against tumor-associated antigens. Acute side effects were mild abdominal pain, pyrexia, diarrhea, and moderate reversible pancytopenia. One patient developed a subphrenic abscess requiring surgical drainage. Eight patients with large volume disease, ie, greater than 2 cm tumor diameter, did not respond to antibody-guided irradiation and died of progressive disease within 9 months of treatment. Sixteen patients had small-volume (less than 2 cm) disease at the time of treatment with radiolabeled antibody. Seven patients failed to respond, and of nine initial responders, four patients remain alive and free from disease 6 months to 3 years from treatment. Analysis of the data on relapse indicated that doses greater than 140 mCi were more effective than lower doses. We conclude that the intraperitoneal administration of 140 mCi or more of 131I-labeled tumor-associated monoclonal antibodies represents a new and potentially effective form of therapy for patients with small-volume stage III ovarian cancer.

What is the optimal approach to the administration of intraperitoneal chemotherapy in ovarian cancer?

2008 ◽  
Vol 18 (Suppl 1) ◽  
pp. 36-39 ◽  
Author(s):  
M. Markman
Keyword(s):  
Ovarian Cancer ◽  
Intraperitoneal Chemotherapy ◽  
Clinical Setting ◽  
Small Volume ◽  
Intraperitoneal Administration ◽  
Advanced Ovarian Cancer ◽  
Primary Treatment ◽  
Evidence Based ◽  
Phase 3 ◽  
Optimal Approach

Three well-designed and conducted randomized phase 3 trials have revealed that the intraperitoneal administration of cisplatin-based chemotherapy as primary treatment of small-volume residual advanced ovarian cancer improves both progression-free and overall survivals compared to an all intravenous cisplatin-based regimen. Based on very reasonable extrapolations from existing evidence-based data, a number of possible “options” can be proposed that use the intraperitoneal route for delivery of chemotherapy in this clinical setting

Point: Intraperitoneal Chemotherapy in the Management of Ovarian Cancer

2004 ◽  
Vol 2 (6) ◽  
pp. 549-554 ◽  
Author(s):  
Maurie Markman
Keyword(s):  
Ovarian Cancer ◽  
Small Volume ◽  
Advanced Ovarian Cancer ◽  
Phase Iii ◽  
Rational Approach ◽  
Pharmacokinetic Studies ◽  
Phase Ii Trials ◽  
Intraperitoneal Therapy ◽  
Phase Iii Trials ◽  
Optimal Approach

Both preclinical considerations and results of phase I safety and pharmacokinetic studies provided support for the argument that intraperitoneal antineoplastic drug delivery should be a rational approach to the management of ovarian cancer. Subsequently conducted phase II trials exploring regional treatment revealed surgically documented objective responses when the approach was employed as a second-line therapy. Recently, the results of three randomized phase III trials have shown that the use of primary cisplatin-based intraperitoneal therapy leads to superior survival compared with intravenous cisplatin-based treatment in patients with small-volume residual advanced ovarian cancer after initial surgical cytoreduction. Further exploration of this unique management strategy is indicated to develop an optimal approach that maintains the demonstrated enhanced efficacy while reducing the toxicity (principally because of cisplatin) of treatment.

scholarly journals Effect of Intraperitoneal Administration of Paclitaxel Combined with Cisplatin in Treatment of Advanced Ovarian Cancer

2019 ◽  
Vol 3 (1) ◽  
Author(s):  
Li Zhao
Keyword(s):  
Ovarian Cancer ◽  
Intraperitoneal Administration ◽  
Advanced Ovarian Cancer ◽  
Control Group ◽  
Double Blind ◽  
T Lymphocyte Subsets ◽  
Significant Difference ◽  
The Difference ◽  
Experimental Group ◽  
Randomization Method

Objective: To analyze the effect of intraperitoneal administration of paclitaxel combined with cisplatin in treatment of advanced ovarian cancer. Method: Fifty-four patients with advanced ovarian cancer in our hospital were randomly selected from the beginning of July 2018 to the end of June 2019. The principle of grouping was based on double-blind randomization method. In experimental group, 27 patients were given intraperitoneal administration of paclitaxel combined with cisplatin. In control group, 27 patients were given intravenous administration of paclitaxel combined with cisplatin. Clinical data of the two groups were compared. Results: Short-term clinical efficacy and T lymphocyte subsets of experimental group were significantly improved when compared with control group. The difference was significant (P<0.05). There was no significant difference in adverse reactions between the two groups (P>0.05). Conclusion: The effect of intraperitoneal administration of paclitaxel combined with cisplatin is ideal for treatment of advanced ovarian cancer patients.

Strategies to examine new compounds for intraperitoneal use in ovarian cancer

2008 ◽  
Vol 18 (Suppl 1) ◽  
pp. 33-35 ◽  
Author(s):  
M. Markman
Keyword(s):  
Ovarian Cancer ◽  
Drug Delivery ◽  
Antineoplastic Agents ◽  
Randomized Trials ◽  
Small Volume ◽  
Advanced Ovarian Cancer ◽  
Clinical Development ◽  
Realistic Potential ◽  
Preclinical Evaluation ◽  
New Compounds

The results of three large well-designed randomized trials demonstrating the favorable impact of primary cisplatin-based chemotherapy on survival in small-volume residual advanced ovarian cancer has stimulated considerable interest in exploration of this route of drug delivery for other antineoplastic agents. A number of relevant properties of both the drugs and the peritoneal cavity need to be considered in preclinical evaluation such that future clinical development will focus on strategies that have a realistic potential for being safe and effective when they enter the clinical arena

Clinical and Scintigraphic Findings in Radiation Myositis Complicating the Intraperitoneal Administration of 198Au

1965 ◽  
Vol 05 (02) ◽  
pp. 188-196
Author(s):  
J. Němec ◽  
J. Kubalt ◽  
S. Vohnout ◽  
J. Schubert ◽  
J. Sudek ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Ascitic Fluid ◽  
Saline Solution ◽  
Intraperitoneal Administration ◽  
Clinical Findings ◽  
Safety Measures ◽  
Muscle Necrosis

SummaryPraeperitoneal administration of colloidal 198Au complicating the treatment of anascitic ovarian cancer is reported. Typical scintiscans and various clinical findings of muscle necrosis and radiation myositis are described. Administration of larger amount of saline solution preceding the radiogold instillation controlled by simultaneous scintiscanning are suggested as safety measures in patients when no ascitic fluid is present.

Sign in / Sign up

Export Citation Format

Share Document